LRRK2 Gene Variants and Mutations

LRRK2 Gene Variants and Mutations

The [LRRK2](/entities/lrrk2) (Leucine-Rich Repeat Kinase 2) gene encodes a large multi-domain protein with kinase activity. Pathogenic variants in LRRK2 are among the most common genetic causes of familial Parkinson's disease.

Overview

| Property | Value | [@investigating]
|----------|-------| [@evidence]
| Gene Symbol | LRRK2 | [@genotypeassociated]
| Full Name | Leucine-Rich Repeat Kinase 2 |
| Chromosomal Location | 12q12 |
| NCBI Gene ID | 120892 |
| OMIM | [609007](https://www.omim.org/entry/609007) |
| Ensembl ID | ENSG00000188906 |
| UniProt ID | [Q5S007](https://www.uniprot.org/uniprotkb/Q5S007) |
| Inheritance | Autosomal Dominant |
| Protein Domains | ROC (Ras of complex), COR, Kinase, LRR, ANK, WD40 |

Function

LRRK2 is a large cytosolic protein (2527 amino acids) with multiple functional domains:

• Kinase domain: Phosphorylates target proteins (including itself through autophosphorylation)
• ROC domain: GTPase activity, regulates protein interactions
• COR domain: Mediates dimerization
• LRR domain: Protein-protein interactions
• WD40 repeat: Scaffold for protein complexes

Normal Functions

...

LRRK2 Gene Variants and Mutations

The [LRRK2](/entities/lrrk2) (Leucine-Rich Repeat Kinase 2) gene encodes a large multi-domain protein with kinase activity. Pathogenic variants in LRRK2 are among the most common genetic causes of familial Parkinson's disease.

Overview

| Property | Value | [@investigating]
|----------|-------| [@evidence]
| Gene Symbol | LRRK2 | [@genotypeassociated]
| Full Name | Leucine-Rich Repeat Kinase 2 |
| Chromosomal Location | 12q12 |
| NCBI Gene ID | 120892 |
| OMIM | [609007](https://www.omim.org/entry/609007) |
| Ensembl ID | ENSG00000188906 |
| UniProt ID | [Q5S007](https://www.uniprot.org/uniprotkb/Q5S007) |
| Inheritance | Autosomal Dominant |
| Protein Domains | ROC (Ras of complex), COR, Kinase, LRR, ANK, WD40 |

Function

LRRK2 is a large cytosolic protein (2527 amino acids) with multiple functional domains:

• Kinase domain: Phosphorylates target proteins (including itself through autophosphorylation)
• ROC domain: GTPase activity, regulates protein interactions
• COR domain: Mediates dimerization
• LRR domain: Protein-protein interactions
• WD40 repeat: Scaffold for protein complexes

Normal Functions

• Neuronal signaling: Regulates various signaling pathways in [neurons](/entities/neurons)
• Protein sorting: Controls vesicular trafficking through Rab GTPase interactions
• Mitochondrial function: Associates with mitochondrial outer membrane
• Synaptic plasticity: Involved in dopamine receptor signaling
• [Autophagy](/entities/autophagy) regulation: Modulates autophagic processes

Disease Associations

Primary Disease

Parkinson's Disease (PD) - LRRK2 is the most common genetic cause of late-onset familial PD, accounting for 5-10% of familial cases and 1-5% of sporadic cases.

Key Pathogenic Mutations

| Mutation | Domain | Effect | Prevalence |
|----------|--------|--------|------------|
| G2019S | Kinase | Increased kinase activity | Most common (~5% familial PD) |
| R1441C | ROC | Impaired GTPase activity | Second most common |
| R1441G | ROC | Impaired GTPase activity | Common in Basque population |
| R1441H | ROC | Impaired GTPase activity | Variable penetrance |
| Y1699C | COR | Altered function | Rare |
| G2385R | WD40 | Risk variant | Asian populations |
| R1628P | WD40 | Risk variant | Asian populations |

Geographic Distribution

• G2019S: Common in European and North African populations (up to 30% of familial PD in some populations)
• R1441G: Highly prevalent in Basque population (up to 50% of familial PD)
• G2385R: Risk factor in East Asian populations

Penetrance

The penetrance of LRRK2 mutations is age-dependent and incomplete:

• G2019S: ~70% by age 80
• R1441C/G: ~30-50% by age 80
• Variable depending on specific mutation and population

Pathogenic Mechanisms

• Kinase hyperactivity: G2019S increases kinase activity, leading to enhanced downstream signaling
• GTPase dysfunction: R1441 mutations impair ROC domain function
• Mitochondrial dysfunction: Altered mitochondrial quality control
• Dysregulated autophagy: Impaired lysosomal and autophagic clearance
• Neuroinflammation: Activation of [microglia](/cell-types/microglia-neuroinflammation) and inflammatory pathways

Expression

LRRK2 is widely expressed in the central and peripheral nervous system:

• Substantia nigra - Dopaminergic neurons (vulnerable in PD)
• [Cortex](/brain-regions/cortex) - Especially frontal and temporal regions
• Striatum - Major target of dopaminergic input
• [Hippocampus](/brain-regions/hippocampus) - Involved in learning and memory
• Peripheral tissues - Kidneys, lungs, immune cells

Expression is also prominent in:

• Kidney and lung tissue
• Immune cells (monocytes, macrophages)

Therapeutic Implications

Current Strategies

• LRRK2 kinase inhibitors: Small molecule inhibitors (e.g., DNL151, BIIB122)
• Antisense oligonucleotides: siRNA approaches to reduce LRRK2 expression
• Protein-protein interaction inhibitors: Targeting ROC-COR or LRR domain interactions

Clinical Trials

• Multiple LRRK2 kinase inhibitors in clinical trials for PD
• Immunotherapy approaches targeting LRRK2-associated pathology

Research Directions

• Personalized medicine: Targeting LRRK2-positive PD patients
• Biomarker development: LRRK2 activity as a disease biomarker
• Neuroprotection: Strategies to prevent dopaminergic neuron loss
• Modulating protein clearance: Enhancing autophagy to clear mutant protein

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease) - Clinical features and pathogenesis
• [Parkinson's Disease Genetic Variants](/diseases/parkinsons-genetic-variants) - Overview of PD genetics
• [LRRK2-Targeting Therapies](/therapeutics/lrrk2-targeting-therapies) - Treatment approaches (if available)
• [Dopamine Signaling in PD](/mechanisms/dopamine-signaling-parkinsons) - Dopaminergic dysfunction

Key Publications

[Paisán-Ruíz et al., Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease (2005)](https://doi.org/10.1016/j.neuron.2004.11.069)

[Zimprich et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology (2004)](https://doi.org/10.1016/j.neuron.2004.11.005)

[Di Fonzo et al., A common missense variant in LRRK2 is a major risk factor for Parkinson's disease (2005)](https://doi.org/10.1016/j.cell.2005.10.035)

[Cookson, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease (2010)](https://doi.org/10.1038/nrn2786)

See Also

• [LRRK2 Gene](/genes/lrrk2) — Leucine-rich repeat kinase 2
• [Parkinson's Disease](/diseases/parkinsons-disease) — LRRK2-linked PD
• [Kinase Signaling](/mechanisms/kinase-signaling) — LRRK2 kinase activity

External Links

• [PdGene: LRRK2](https://www.pdgene.org/)
• [PubMed: LRRK2 Variants](https://pubmed.ncbi.nlm.nih.gov/)

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Convergent molecular pathways to inherited Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/41719940/) (2026 Apr) - Current opinion in cell biology
• [Investigating the Genetic Relationship Between Vitamin B12 Metabolism and Parkinson Disease.](https://pubmed.ncbi.nlm.nih.gov/41710648/) (2026 Apr) - Neurology. Genetics
• [No evidence for the LRRK2 p.L1795F variant in a Southern Italian cohort with Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/41500415/) (2026 Mar 20) - Gene
• [Genotype-associated outcomes after deep brain stimulation in Parkinson's disease: a systematic review, meta-analysis and epigenetic implications.](https://pubmed.ncbi.nlm.nih.gov/41823280/) (2026 Mar 13) - Neurologia i neurochirurgia polska
• [LRRK2 kinase mediates increased GCase activity in microglia in response to IFNγ-induced proinflammatory stimulation.](https://pubmed.ncbi.nlm.nih.gov/41786767/) (2026 Mar 6) - NPJ Parkinson's disease

References